SCHEMBL3756866

SCHEMBL3756866

COc1ccc(S(=O)(=O)n2c(C)c(C(=O)N3CCCN(C(=O)OC(C)(C)C)CC3)c3ccccc32)c2ccccc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AVPR1B P47901 5/20 0.67
ALDH1A1 P00352 4/20 0.52
TSHR P16473 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
KDM4E B2RXH2 2/20 0.43
HTT P42858 2/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
AVPR1A P37288 1/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NPC1 O15118 1/20 0.41
MAPK1 P28482 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
HTR6 P50406 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3742342 0.85 ALDH1A1 (0.52) AVPR1BALDH1A1TSHRSMN1; SMN2KDM4E
Trifluoroacetic Acid SCHEMBL3749338 0.81 AVPR1B (0.63) AVPR1BALDH1A1TSHRSMN1; SMN2AVPR1A
SCHEMBL3754777 0.77 ALDH1A1 (0.48) AVPR1BALDH1A1TSHRSMN1; SMN2KDM4E
SCHEMBL3747271 0.76 ALDH1A1 (0.46) AVPR1BALDH1A1TSHRSMN1; SMN2HTT
SCHEMBL3759249 0.75 ALDH1A1 (0.45) AVPR1BALDH1A1TSHRSMN1; SMN2KDM4E
SCHEMBL3750899 0.75 ACLY (0.46) AVPR1BALDH1A1TSHRSMN1; SMN2KDM4E
SCHEMBL4325589 0.73 KMT2A (0.57) ALDH1A1TSHRSMN1; SMN2KDM4EHTT
SCHEMBL31399732 0.73 ALDH1A1 (0.65) ALDH1A1TSHRSMN1; SMN2KDM4EHTT
SCHEMBL3746686 0.71 ALDH1A1 (0.46) AVPR1BALDH1A1TSHRSMN1; SMN2HTR6
Trifluoroacetic Acid SCHEMBL3744508 0.67 AVPR1B (0.63) AVPR1BALDH1A1TSHRSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7838518-B2 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders N.V. ORGANON (NL) 2010-11-23 US disclosed
EP-1476151-B1 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ORGANON NV (NL) 2008-07-16 EP disclosed
US-20050154023-A1 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders MERCK SHARP & DOHME B.V. (NL) 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154023-A1 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders TPH1, HTR1A, HTR1D AVPR1B 966/4885ALDH1A1 1048/4885TSHR 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.